Sector News

Dr. Carsten Brunn to lead Bayer's pharmaceuticals business in America

January 19, 2017
Life sciences

Bayer today announced the appointment of Dr. Carsten Brunn as President of its Pharmaceuticals business in the Americas, comprising the United States, Canada, Central and Latin America.

In this role, Dr. Brunn will report to Dieter Weinand, member of the Board of Management of Bayer AG and President of the Pharmaceutical division.

“Carsten is a strategic and highly respected leader in the pharmaceutical industry and I’m delighted to have him lead the company’s largest pharmaceutical business worldwide,” said Dieter Weinand. “Carsten’s global perspective and proven track record of successful operational execution at the local level will be a critical asset to us as we continue to build on our current momentum in the U.S. and across the Americas region.”

Previously, Dr. Brunn was Head of Bayer’s Pharmaceuticals Commercial Operations in Japan, a role he held since 2013. He served as the Chairman of European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan, an organization representing 24 R&D-based innovative pharmaceutical companies in Japan. Dr. Brunn joined Bayer in 2011 as Global Head of Primary Care based in Beijing, China. Prior to joining Bayer, Dr. Brunn held a number of senior leadership roles at companies including Eli Lilly, Novartis, and Bausch & Lomb in Europe, Asia, and the United States.

“It has been an incredibly rewarding experience to lead Bayer’s pharmaceuticals organization in Japan, and I am honored to have the opportunity to join such an established team here in the United States,” said Carsten Brunn. “The U.S. is one of the most important and innovative pharmaceutical markets in the world, where we are in a solid period of consistent growth with strong performance across all our therapeutic areas. I’m thrilled to bring my experiences from other markets to this organization as we continue to build on our strengths and meet the needs of patients.”

Dr. Brunn graduated from the University of Freiburg in Germany with a Master of Science in Pharmaceutical Science. In addition, he studied at the University of Washington under a research scholarship and later received his PhD in Chemistry from the University of Hamburg in Germany. He completed his executive education at the London Business School.

Source: Bayer

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend